within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH02_Romidepsin;

model Romidepsin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.694444444444445e-06,
    adminDuration = 600,
    adminMass = 14 / 1000000,
    adminCount = 1,
    Vd = 0.393,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 3.069,
    k12 = 2.8611111111111113e-05,
    k21 = 2.8611111111111113e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Romidepsin</td></tr><tr><td>ATC code:</td><td>L01XH02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>14</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>393</td><td>L</td></tr>
    <tr><td>clearance:</td><td>20.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Romidepsin is a cyclic peptide histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is approved by regulatory agencies such as the FDA for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with advanced cancers, administered intravenous infusion over 4 hours. Parameters derived from population PK modeling.</p><h4>References</h4><ol><li><p>Peer, CJ, et al., &amp; Figg, WD (2018). A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer chemotherapy and pharmacology</i> 82(3) 565–570. DOI:<a href=\"https://doi.org/10.1007/s00280-018-3631-7\">10.1007/s00280-018-3631-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29951694/\">https://pubmed.ncbi.nlm.nih.gov/29951694</a></p></li><li><p>Gerber, DE, et al., &amp; Schiller, JH (2015). Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. <i>Lung cancer (Amsterdam, Netherlands)</i> 90(3) 534–541. DOI:<a href=\"https://doi.org/10.1016/j.lungcan.2015.10.008\">10.1016/j.lungcan.2015.10.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26474959/\">https://pubmed.ncbi.nlm.nih.gov/26474959</a></p></li><li><p>Stadler, WM, et al., &amp; Thompson, JA (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. <i>Clinical genitourinary cancer</i> 5(1) 57–60. DOI:<a href=\"https://doi.org/10.3816/CGC.2006.n.018\">10.3816/CGC.2006.n.018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16859580/\">https://pubmed.ncbi.nlm.nih.gov/16859580</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XH02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Romidepsin;
